The genetic epidemiology of neurodegenerative disease
Open accessThe DOI matches its Crossref record; 103 of the 106 references it cites were found in a registry or an index.
Abstract
Gene defects play a major role in the pathogenesis of degenerative disorders of the nervous system.In fact, it has been the very knowledge gained from genetic studies that has allowed the elucidation of the molecular mechanisms underlying the etiology and pathogenesis of many neurodegenerative disorders.In this review, we discuss the current status of genetic epidemiology of the most common neurodegenerative diseases: Alzheimer disease, Parkinson disease, Lewy body dementia, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, and prion diseases, with a particular focus on similarities and differences among these syndromes. The complexities of common diseasesFamilial aggregation had been recognized as a prominent characteristic of many neurodegenerative disorders decades before the underlying molecular genetic or biochemical properties were known.It was often the identification of specific, disease-segregating mutations in previously unknown genes that directed the attention to certain proteins and pathways that are now considered crucial in the pathogenesis of these diseases.These include mutations in the β-amyloid (Aβ) precursor protein, causing Alzheimer disease (AD); in α-synuclein, causing Parkinson disease (PD); or in microtubule-associated protein tau, causing frontotemporal dementia (FTD) with parkinsonism.Another feature observed in most common neurodegenerative diseases -as well as in other common disorders -is a dichotomy between familial (rare) and seemingly nonfamilial (common) forms.The latter are also frequently described as "sporadic" or "idiopathic," although there is a growing body of evidence suggesting that a large proportion of these cases are also significantly influenced by genetic factors.These risk genes are likely to be numerous, displaying intricate patterns of interaction with each other as well as with nongenetic variable, and -unlike classical Mendelian ("simplex") disorders -exhibit no simple or single mode of inheritance.Hence, the genetics of these diseases has been labeled "complex."A popular conception regarding the genetic makeup of complex diseases is the "common disease/common variant" (CD/CV) hypothesis (1).According to this theory common disorders are also governed by common DNA variants (such as single nucleotide polymorphisms.These variants significantly increase disease risk but are insufficient to actually cause a specific disorder.Current empirical and theoretical data support this hypothesis, although there remains great uncertainty as to the number of the underlying risk factors and their specific effect sizes.In this context, it is noteworthy that even recent genetic advances in the study of complex diseases such as AD or diabetes likely only represent the most obvi-ous, most extreme cases of the underlying risk spectrum (Figure 1; ref.2).In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e.APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.The identification of these genes early in the study of AD genetics was possible due to the combination of several favorable circumstances, such as the presence of multiple independent mutations in the same locus and the availability of extended, multigenerational pedigrees for DNA genotyping and sequencing (in the case of PSEN1) or a large attributable fraction to the overall genetic variance, resulting from relatively high allele frequency and pronounced effect size (in the case of APOE).However, identification of disease genes that make smaller overall contributions to the genetic spectrum (because of only few mutational events; e.g., PSEN2), or risk factors with smaller effect sizes (i.e.odds ratios [ORs] ranging between 2 and 3), will require much larger samples and possibly more sensitive and efficient analytic tools to enable consistent detection across study populations (2).Additional, and commonly cited, problems in finding complex disease genes beyond the most obvious are multiple testing, publication bias, and questionable replication (3-5).Multiple testing can be placed under the larger category of "avoidable false positive" findings, which are also caused by testing insufficiently sized samples, using inappropriate matching of cases versus controls, stratifying populations, and choosing inadequate analysis strategies, etc. Publication bias, on the other hand, which indicates the higher a priori likelihood of a positive finding being published as opposed to a negative one, may have been a possible source of serious bias in the early days.However, there is only relatively little empirical evidence that publication bias actually represents a common or significant source of error in current publications investigating the genetics of a number of disorders (e.g., refs.6-12).The sheer number of publications in the AD gene
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated levels of Amyloid-β (Aβ) peptide initiates a cascade of events that ultimately result in Alzheimer’s disease (AD) [1–4].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 4×
“The most frequently involved gene in recessive parkinsonism is parkin (PRKN) on chromosome 6q25 (33, 41), which causes nearly half of all early-onset PD cases.”
BackgroundInfluentialGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 5×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluentialα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“AD APP (15) Aβ precursor protein 21q21 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) and aggregation AD APOE (21, 22) Apolipoprotein E 19q13 Risk factor Unknown (Aβ aggregation? lipid metabolism?) AD PSEN1 (16) Presenilin 1 14q24 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) AD PSEN2 (17, 18) Presenilin 2 1q…”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 9×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluentialMcKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960 · cited 11×
“The correlation between 4-repeat tau and genetic variants in MAPT is further supported by genetic association studies showing almost unanimous support for an MAPT risk haplotype (H1) in samples from patients with PSP or CBD, both characterized by the abundance of 4-repeat tau.”
BackgroundInfluentialAssociation of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498 · cited 1×
“org Volume 115 Number 6 June 2005 same mutation was also found in families segregating more typical FTD (65).”
BackgroundHereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481 · cited 6×
“34]; PTEN-induced putative kinase I [PINK1 or PARK6; ref.”
BackgroundInfluentialMutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005 · cited 1×
“AD APP (15) Aβ precursor protein 21q21 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) and aggregation AD APOE (21, 22) Apolipoprotein E 19q13 Risk factor Unknown (Aβ aggregation? lipid metabolism?) AD PSEN1 (16) Presenilin 1 14q24 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) AD PSEN2 (17, 18) Presenilin 2 1q…”
BackgroundMutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778 · cited 5×
“While Lewy bodies are typically not found in brains of patients bearing parkin mutations, it is currently unclear whether these are present in PD cases with mutations in DJ1 and PINK1.”
BackgroundInfluentialCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 6×
“However, identification of disease genes that make smaller overall contributions to the genetic spectrum (because of only few mutational events; e.g., PSEN2), or risk factors with smaller effect sizes (i.e. odds ratios [ORs] ranging between 2 and 3), will require much larger samples and possibly more sensitive and eff…”
BackgroundInfluentialCloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405 · cited 1×
“AD APP (15) Aβ precursor protein 21q21 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) and aggregation AD APOE (21, 22) Apolipoprotein E 19q13 Risk factor Unknown (Aβ aggregation? lipid metabolism?) AD PSEN1 (16) Presenilin 1 14q24 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) AD PSEN2 (17, 18) Presenilin 2 1q…”
BackgroundA polymorphic DNA marker genetically linked to Huntington's disease
Gusella, J. F., Wexler, N. S., Conneally, P. M., Naylor, S. L., Anderson, M. A., Tanzi, R. E., Watkins, P. C., Ottina, K., Wallace, M. R., Sakaguchi, A. Y., et al. (1983) · Nature · doi:10.1038/306234a0 · Cited by 2,347 · cited 1×
“the HD gene was the first autosomal disease locus to be mapped by genetic linkage analysis (to chromosome 4q16), in 1983 (86).”
BackgroundRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 6×
“However, identification of disease genes that make smaller overall contributions to the genetic spectrum (because of only few mutational events; e.g., PSEN2), or risk factors with smaller effect sizes (i.e. odds ratios [ORs] ranging between 2 and 3), will require much larger samples and possibly more sensitive and eff…”
BackgroundInfluentialα-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Lohmueller, K. E., Pearce, C. L., Pike, M., Lander, E. S., & Hirschhorn, J. N. (2003) · Nature Genetics · doi:10.1038/ng1071 · Cited by 1,900
Searching for genetic determinants in the new millennium
Risch, N. J. (2000) · Nature · doi:10.1038/35015718 · Cited by 1,839 · cited 1×
“odds ratios [ORs] ranging between 2 and 3), will require much larger samples and possibly more sensitive and efficient analytic tools to enable consistent detection across study populations (2).”
BackgroundReplication validity of genetic association studies
Ioannidis, J. P. A., Ntzani, E. E., Trikalinos, T. A., & Contopoulos-Ioannidis, D. G. (2001) · Nature Genetics · doi:10.1038/ng749 · Cited by 1,832
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,571 · cited 1×
“At least 6 additional candidate PD loci have been described, including putative disease-causing mutations in the ubiquitin carboxy-terminal hydrolase L1 (UCHL1) on chromosome 4p14 (46), and in a nuclear receptor of subfamily 4 (NR4A2, or NURR1; ref.”
BackgroundSchmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525 · cited 1×
“AD APP (15) Aβ precursor protein 21q21 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) and aggregation AD APOE (21, 22) Apolipoprotein E 19q13 Risk factor Unknown (Aβ aggregation? lipid metabolism?) AD PSEN1 (16) Presenilin 1 14q24 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) AD PSEN2 (17, 18) Presenilin 2 1q…”
BackgroundMcKhann, G. M. (2001) · Archives of Neurology · doi:10.1001/archneur.58.11.1803 · Cited by 1,472 · cited 1×
“FTD is a heterogenous group of syndromes defined clinically by a gradual and progressive change in behavior and personal conduct and/or by a gradual and progressive language dysfunction (62).”
BackgroundProblems of reporting genetic associations with complex outcomes
Colhoun, H. M., McKeigue, P. M., & Smith, G. D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12715-8 · Cited by 1,204
The New Genomics: Global Views of Biology
Lander, E. S. (1996) · Science · doi:10.1126/science.274.5287.536 · Cited by 1,174 · cited 1×
“plex diseases is the “common disease/common variant” (CD/CV) hypothesis (1).”
BackgroundRosen, D. (1993) · Nature · doi:10.1038/364362c0 · Cited by 922
Homozygous prion protein genotype predisposes to sporadic Creutzfeldt–Jakob disease
Palmer, M. S., Dryden, A. J., Hughes, J. T., & Collinge, J. (1991) · Nature · doi:10.1038/352340a0 · Cited by 890 · cited 1×
“M/M or V/V) is disoportionally more frequent in sCJD than the M/V genotype (96).”
BackgroundParkinson Disease in Twins: An Etiologic Study
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 867
Linkage of a prion protein missense variant to Gerstmann–Sträussler syndrome
Hsiao, K., Baker, H. F., Crow, T. J., Poulter, M., Owen, F., Terwilliger, J. D., Westaway, D., Ott, J., & Prusiner, S. B. (1989) · Nature · doi:10.1038/338342a0 · Cited by 849
Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302553 · Cited by 785 · cited 1×
“loci (24) — and probably also EOFAD loci (25, 26) — remain to be identified, since the 4 known genes together account for probably”
BackgroundHamilton, R. L. (2000) · Brain Pathology · doi:10.1111/j.1750-3639.2000.tb00269.x · Cited by 754 · cited 5×
“However, identification of disease genes that make smaller overall contributions to the genetic spectrum (because of only few mutational events; e.g., PSEN2), or risk factors with smaller effect sizes (i.e. odds ratios [ORs] ranging between 2 and 3), will require much larger samples and possibly more sensitive and eff…”
BackgroundInfluentialFaraone, S. V., Doyle, A. E., Mick, E., & Biederman, J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1052 · Cited by 753
Yang, Y., Hentati, A., Deng, H.-X., Dabbagh, O., Sasaki, T., Hirano, M., Hung, W.-Y., Ouahchi, K., Yan, J., Azim, A. C., et al. (2001) · Nature Genetics · doi:10.1038/ng1001-160 · Cited by 743 · cited 1×
“Recently, mutations in a second gene (ALS2; encoding alsin) were identified in independent families with a rare, juvenile-onset autosomal recessive form of ALS and primary lateral sclerosis, a syndrome restricted to upper motor neuron degeneration (79, 80).”
BackgroundA gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2
Hadano, S., Hand, C. K., Osuga, H., Yanagisawa, Y., Otomo, A., Devon, R. S., Miyamoto, N., Showguchi-Miyata, J., Okada, Y., Singaraja, R., et al. (2001) · Nature Genetics · doi:10.1038/ng1001-166 · Cited by 678 · cited 1×
“Recently, mutations in a second gene (ALS2; encoding alsin) were identified in independent families with a rare, juvenile-onset autosomal recessive form of ALS and primary lateral sclerosis, a syndrome restricted to upper motor neuron degeneration (79, 80).”
BackgroundA new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1
Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., & Obata, F. (2002) · Annals of Neurology · doi:10.1002/ana.10113 · Cited by 667
Sporadic and familial CJD: classification and characterisation
Gambetti, P., Kong, Q., Zou, W., Parchi, P., & Chen, S. G. (2003) · British Medical Bulletin · doi:10.1093/bmb/66.1.213 · Cited by 569
Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease
Collinge, J., Palmer, M. S., & Dryden, A. J. (1991) · The Lancet · doi:10.1016/0140-6736(91)93128-v · Cited by 556
Valente, E. M., Bentivoglio, A. R., Dixon, P. H., Ferraris, A., Ialongo, T., Frontali, M., Albanese, A., & Wood, N. W. (2001) · The American Journal of Human Genetics · doi:10.1086/319522 · Cited by 493 · cited 1×
“org Volume 115 Number 6 June 2005 mosome, additional PD-causing mutations were subsequently discovered in PINK1 (35) following positive linkage evidence to this region (45).”
BackgroundMutations in NR4A2 associated with familial Parkinson disease
Le, W.-D., Xu, P., Jankovic, J., Jiang, H., Appel, S. H., Smith, R. G., & Vassilatis, D. K. (2003) · Nature Genetics · doi:10.1038/ng1066 · Cited by 487
(2002) · doi:10.1016/s0896-6273(02)01125-x · Cited by 473
Figlewicz, D. A., Krizus, A., Martinoli, M. G., Meininger, V., Dib, M., Rouleau, G. A., & Julien, J.-P. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.10.1757 · Cited by 468
New Frontiers in Alzheimer's Disease Genetics
Tanzi, R. E., & Bertram, L. (2001) · Neuron · doi:10.1016/s0896-6273(01)00476-7 · Cited by 463
Self-citationCruts, M., van Duijn, C. M., Backhovens, H., Van den Broeck, M., Wehnert, A., Serneels, S., Sherrington, R., Hutton, M., Hardy, J., St George-Hyslop, P. H., et al. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.1.43 · Cited by 432 · cited 1×
“loci (24) — and probably also EOFAD loci (25, 26) — remain to be identified, since the 4 known genes together account for probably”
BackgroundFrontal lobe degeneration of non-Alzheimer type. I. Neuropathology
Brun, A. (1987) · Archives of Gerontology and Geriatrics · doi:10.1016/0167-4943(87)90021-5 · Cited by 396
Genetic evidence for the involvement of τ in progressive supranuclear palsy
Conrad, C., Andreadis, A., Trojanowski, J. Q., Dickson, D. W., Kang, D., Chen, X., Wiederholt, W., Hansen, L., Masliah, E., Thal, L. J., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410410222 · Cited by 388
The role of pathogenic DJ‐1 mutations in Parkinson's disease
Abou‐Sleiman, P. M., Healy, D. G., Quinn, N., Lees, A. J., & Wood, N. W. (2003) · Annals of Neurology · doi:10.1002/ana.10675 · Cited by 383
Siddique, T., Figlewigz, D. A., Pericak-Vance, M. A., Haines, J. L., Rouleau, G., Jeffers, A. J., Sapp, P., Hung, W.-Y., Bebout, J., McKenna-Yasek, D., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105163242001 · Cited by 382
PARK7, a Novel Locus for Autosomal Recessive Early-Onset Parkinsonism, on Chromosome 1p36
van Duijn, C. M., Dekker, M. C. J., Bonifati, V., Galjaard, R. J., Houwing-Duistermaat, J. J., Snijders, P. J. L. M., Testers, L., Breedveld, G. J., Horstink, M., Sandkuijl, L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/322996 · Cited by 379
Matsumine, H., Saito, M., Shimoda‐Matsubayashi, S., Tanaka, H., Ishikawa, A., Nakagawa-Hattori, Y., Yokochi, M., Kobayashi, T., Igarashi, S., Takano, H., et al. (1997) · Europe PMC (PubMed Central) · Cited by 377
A full genome scan for late onset Alzheimer's disease
Kehoe, P. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.2.237 · Cited by 357 · cited 1×
“region on 12p12, which was found by 2 different research groups in a sample different from the original chromosome 12 linkage report (59, 60).”
Backgroundalpha-synuclein gene haplotypes are associated with Parkinson's disease
Farrer, M. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.17.1847 · Cited by 340
Andersen, P. M., Nilsson, P., Ala-Hurula, V., Keränen, M.-L., Tarvainen, I., Haltia, T., Nilsson, L., Binzer, M., Forsgren, L., & Marklund, S. L. (1995) · Nature Genetics · doi:10.1038/ng0595-61 · Cited by 322 · cited 1×
“Meanwhile, more than 100 mutations in SOD1 have been described in over 200 pedigrees with FALS worldwide, and all but 1 of the known SOD1 mutations are inherited in an autosomal dominant fashion (75).”
BackgroundHosler, B. A. (2000) · JAMA · doi:10.1001/jama.284.13.1664 · Cited by 315 · cited 2×
“significant linkage to chromosome 9q21 in families with ALS and FTD (83).”
BackgroundPocchiari, M. (2004) · Brain · doi:10.1093/brain/awh249 · Cited by 302 · cited 1×
“faster disease progression than heterozygosity in nearly all genetic as well as sporadic (including iatrogenic) forms of prion diseases, and in most instances, the M/M genotype is associated with the most aggressive course of disease (98).”
BackgroundThe Number of Trait Loci in Late-Onset Alzheimer Disease
Daw, E. W., Payami, H., Nemens, E. J., Nochlin, D., Bird, T. D., Schellenberg, G. D., & Wijsman, E. M. (2000) · The American Journal of Human Genetics · doi:10.1086/302710 · Cited by 295 · cited 1×
“loci (24) — and probably also EOFAD loci (25, 26) — remain to be identified, since the 4 known genes together account for probably”
BackgroundComplete Genomic Screen in Parkinson Disease: Evidence for Multiple Genes
Scott, W. K., Nance, M. A., Watts, R. L., Hubble, J. P., Koller, W. C., Lyons, K., Pahwa, R., Stern, M. B., Colcher, A., Hiner, B. C., et al. (2001) · JAMA · doi:10.1001/jama.286.18.2239 · Cited by 282
UCHL1 is a Parkinson's disease susceptibility gene
Maraganore, D. M., Lesnick, T. G., Elbaz, A., Chartier‐Harlin, M., Gasser, T., Krüger, R., Hattori, N., Mellick, G. D., Quattrone, A., Satoh, J., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20017 · Cited by 262
Results of a high-resolution genome screen of 437 Alzheimer's Disease families
Blacker, D. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg007 · Cited by 262 · cited 6×
“This overlaps with a location shown to be linked to AD (84), which possibly indicates a common pathophysiological basis for neurodegeneration or dementia in these 2 disorders.”
BackgroundInfluentialStathopulos, P. B., Rumfeldt, J. A. O., Scholz, G. A., Irani, R. A., Frey, H. E., Hallewell, R. A., Lepock, J. R., & Meiering, E. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1237797100 · Cited by 258
Lasky‐Su, J. A., Faraone, S. V., Glatt, S. J., & Tsuang, M. T. (2005) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30104 · Cited by 256
Frontal lobe degeneration of non-Alzheimer type.
Gustafson, L., Brun, A., & Passant, U. (1992) · PubMed · Cited by 242
Rubinsztein, D. C., Leggo, J., Chiano, M., Dodge, A., Norbury, G., Rosser, E., & Craufurd, D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3872 · Cited by 238 · cited 1×
“The most promising of these is located on chromosome 6q25, close to the glutamate receptor, ionotropic, kainate 2 (GRIK2), which has been associated with a younger HD onset age in some studies; this potentially supports the notion of glutamate-induced excitotoxicity in the pathogenesis of HD (90, 91).”
BackgroundNeurodegeneration: The Molecular Pathology of Dementia and Movement Disorders
Cochran, E. J. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.2.182 · Cited by 215
A novel presenilin 1 mutation associated with Pick's disease but not β‐amyloid plaques
Dermaut, B., Kumar‐Singh, S., Engelborghs, S., Theuns, J., Rademakers, R., Saerens, J., Pickut, B. A., Peeters, K., Van Den Broeck, M., Vennekens, K., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20083 · Cited by 212 · cited 9×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluentialPericak-Vance, M. A. (1997) · JAMA · doi:10.1001/jama.1997.03550150041033 · Cited by 206
Phenotypic correlations in FTDP-17
Reed, L. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00202-5 · Cited by 202 · cited 1×
“, segregating with the R406W mutation in exon 13 (66, 67).”
BackgroundAssociation of Single-Nucleotide Polymorphisms of the Tau Gene With Late-Onset Parkinson Disease
Martin, E. R. (2001) · JAMA · doi:10.1001/jama.286.18.2245 · Cited by 191
Assessing publication bias in genetic association studies: evidence from a recent meta-analysis
Munafò, M. R., Clark, T. G., & Flint, J. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2004.06.011 · Cited by 168 · cited 1×
“Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder.”
MethodAPOE-ε2 allele associated with higher prevalence of sporadic Parkinson disease
Huang, X., Chen, P., & Poole, C. (2004) · Neurology · doi:10.1212/01.wnl.0000130159.28215.6a · Cited by 159
Epidemiology and genetics of frontotemporal dementia/Pick's disease
Bird, T. D., Knopman, D. S., Swieten, J. C. V., Rosso, S. M., Feldman, H., Tanabe, H., Graff‐Radford, N. R., Geschwind, D. H., Verpillat, P., & Hutton, M. L. (2003) · Annals of Neurology · doi:10.1002/ana.10572 · Cited by 150 · cited 2×
“They probably account for less than half of the genetic variance in familial FTD (64).”
BackgroundGenetic epidemiology of amyotrophic lateral sclerosis
Majoor‐Krakauer, D., Willems, P., & Hofman, A. (2003) · Clinical Genetics · doi:10.1046/j.0009-9163.2002.00001.x · Cited by 147 · cited 1×
“Familial ALS (FALS) is observed in approximately 10% of all cases, but substantially more ALS cases are suspected to be influenced by genetic factors (72).”
BackgroundTanzi, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8593 · Cited by 143 · cited 1×
“dominant fashion, while late-onset AD (LOAD) without obvious familial segregation is thought to be explained by the CD/CV hypothesis (14).”
BackgroundProtein aggregation in motor neurone disorders
Wood, J. D., Beaujeux, T. P., & Shaw, P. J. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.0305-1846.2003.00518.x · Cited by 137
Evidence for the GluR6 gene associated with younger onset age of Huntington’s disease
MacDonald, M. E., Vonsattel, J. P., Srinidhi, J., Couropmitree, N. N., Cupples, L. A., Bird, E. D., Gusella, J. F., & Myers, R. H. (1999) · Neurology · doi:10.1212/wnl.53.6.1330 · Cited by 132 · cited 1×
“The most promising of these is located on chromosome 6q25, close to the glutamate receptor, ionotropic, kainate 2 (GRIK2), which has been associated with a younger HD onset age in some studies; this potentially supports the notion of glutamate-induced excitotoxicity in the pathogenesis of HD (90, 91).”
BackgroundTau gene and Parkinson's disease: a case-control study and meta-analysis
Healy, D. G., Abou-Sleiman, P. M., Lees, A. J., Casas, J. P., Quinn, N., Bhatia, K., Hingorani, A. D., & Wood, N. W. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.026203 · Cited by 127
A Genome Scan for Modifiers of Age at Onset in Huntington Disease: The HD MAPS Study
Li, J.-L., Hayden, M. R., Almqvist, E. W., Brinkman, R. R., Durr, A., Dodé, C., Morrison, P. J., Suchowersky, O., Ross, C. A., Margolis, R. L., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/378133 · Cited by 126 · cited 1×
“A recent full-genome screen aimed at identifying these genes has revealed several suggestive linkage regions (89).”
BackgroundFarrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Autocatalytic self-propagation of misfolded prion protein
Bieschke, J., Weber, P., Sarafoff, N., Beekes, M., Giese, A., & Kretzschmar, H. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404650101 · Cited by 123
Scott, W. K., Grubber, J. M., Conneally, P. M., Small, G. W., Hulette, C. M., Rosenberg, C. K., Saunders, A. M., Roses, A. D., Haines, J. L., & Pericak‐Vance, M. A. (2000) · The American Journal of Human Genetics · doi:10.1086/302828 · Cited by 120 · cited 1×
“For instance, follow-up analyses to the original AD full-genome screen that led to the description of linkage to chromosome 12 (56) found evidence for considerable genetic heterogeneity in the original study population (57).”
BackgroundMayeux, R., Sano, M., Chen, J., Tatemichi, T., & Stern, Y. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530150037014 · Cited by 117 · cited 1×
“While segregation and twin studies conclusively suggest a major role of genetic factors in this form of AD (20), to date, only 1 such factor has been established, the ε4 allele of the apolipoprotein E gene on chromosome 19q13 (APOE; Table 1; refs.”
BackgroundApolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis
Verpillat, P., Camuzat, A., Hannequin, D., Thomas-Antérion, C., Puel, M., Belliard, S., Dubois, B., Didic, M., Lacomblez, L., Moreaud, O., et al. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200820 · Cited by 110 · cited 1×
“Interestingly, and similar to equivalent studies done in PD, a recent metaanalysis on all data published for APOE in FTD detected a significant risk effect associated with the ε2-allele but no significant results with ε4 (70).”
ResultKanekura, K., Hashimoto, Y., Niikura, T., Aiso, S., Matsuoka, M., & Nishimoto, I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313236200 · Cited by 96
Finckh, U., van Hadeln, K., Müller‐Thomsen, T., Alberici, A., Binetti, G. G., Hock, C., Nitsch, R. M., Stoppe, G., Reiss, J., & Gal, A. (2003) · Neurogenetics · doi:10.1007/s10048-003-0157-9 · Cited by 78 · cited 1×
“mer, more than 3 dozen genes have been significantly associated with AD in the past (27, 28).”
BackgroundRademakers, R., Dermaut, B., Peeters, K., Cruts, M., Heutink, P., Goate, A., & Broeckhoven, C. V. (2003) · Human Mutation · doi:10.1002/humu.10269 · Cited by 77 · cited 1×
“, segregating with the R406W mutation in exon 13 (66, 67).”
BackgroundEpidemiologic study of 203 sibling pairs with Parkinson’s disease
Maher, N. E., Golbe, L. I., Lazzarini, A. M., Mark, M. H., Currie, L. J., Wooten, G. F., Saint‐Hilaire, M., Wilk, J. B., Volcjak, J. S., Maher, J. E., et al. (2002) · Neurology · doi:10.1212/wnl.58.1.79 · Cited by 73
Kuznetsova, T., Staessen, J. A., Wang, J., Gąsowski, J., Nikitin, Y., Ryabikov, A. N., & Fagard, R. H. (2000) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001055 · Cited by 73
Huntington's disease: CAG genetics expands neurobiology.
Gusella, J., & MacDonald, M. (1995) · Current Opinion in Neurobiology · doi:10.1016/0959-4388(95)80072-7 · Cited by 61 · cited 1×
“org Volume 115 Number 6 June 2005 1455 mean repeat length in HD patients is 40–45, although variability is quite wide, ranging from 35 to 120 repeats (88), displaying an inverse correlation with onset age.”
BackgroundLRRK2 mutations and Parkinsonism
Albrecht, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)74810-8 · Cited by 58
Analysis of tau haplotypes in Pick’s disease
Morris, H. R., Baker, M., Yasojima, K., Houlden, H., Khan, M. N., Wood, N. W., Hardy, J., Grossman, M., Trojanowski, J. Q., Révész, T., et al. (2002) · Neurology · doi:10.1212/wnl.59.3.443 · Cited by 57 · cited 7×
“Additional mutations in ALS2 have also been described in families suffering from infantile-onset ascending hereditary spastic paralysis, which suggests considerable phenotypic variability of the ALS2 mutations.”
BackgroundInfluentialFamilial Occurrence of Dementia With Lewy Bodies
Tsuang, D. W., DiGiacomo, L., & Bird, T. D. (2004) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200403000-00009 · Cited by 48 · cited 1×
“While a familial aggregation of LBD has been described (55), the identification of specific LBD genetic factors is complicated by its still-uncertain phenotypic classification, in particular its distinction from AD and PDD.”
BackgroundImportant Link between Dementia Subtype and Apolipoprotein E: a Meta-analysis
Bang, O. Y., Kwak, Y. T., Joo, I. S., & Huh, K. (2003) · Yonsei Medical Journal · doi:10.3349/ymj.2003.44.3.401 · Cited by 34 · cited 1×
“However, a moderate risk effect of this allele was recently supported by metaanalysis on LBD case-control studies from 2000 to 2004 (61).”
BackgroundCurtis, D., North, B. V., & Sham, P. C. (2001) · Annals of Human Genetics · doi:10.1046/j.1469-1809.2001.6550473.x · Cited by 33 · cited 1×
“region on 12p12, which was found by 2 different research groups in a sample different from the original chromosome 12 linkage report (59, 60).”
BackgroundResults of a high-resolution genome screen of 437 Alzheimer's Disease families
Blacker, D. (2002) · Human Molecular Genetics · doi:10.1093/hmg/12.1.23 · Cited by 32
Disordered proteins in dementia
Ingelsson, M., & Hyman, B. T. (2002) · Annals of Medicine · doi:10.1080/078538902320322529 · Cited by 20 · cited 6×
“Additional mutations in ALS2 have also been described in families suffering from infantile-onset ascending hereditary spastic paralysis, which suggests considerable phenotypic variability of the ALS2 mutations.”
BackgroundInfluentialProblems and Solutions in the Genetic Analysis of Late-Onset Alzheimer’s Disease
Hardy, J., Myers, A., & Vrièze, F. W. (2004) · Neurodegenerative Diseases · doi:10.1159/000080988 · Cited by 17
Epidemiologic study of 203 sibling pairs with Parkinson’s disease: The GenePD study
(2002) · Neurology · doi:10.1212/wnl.58.7.1136-a · Cited by 15
Familial Occurrence of Dementia With Lewy Bodies
Tsuang, D. W. (2004) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.12.2.179 · Cited by 6
A note of caution on correlation between sibling pairs
de la Fuente‐Fernández, R. (2003) · Neurology · doi:10.1212/wnl.60.9.1561 · Cited by 3
Research works printed but not linked: 1
- [92]Prusiner, S.B. 1998. Prions. Proc. Natl. Acad. Sci. U. S. A. 95 :13363-13383.
Cited by
Nitric Oxide and Peroxynitrite in Health and Disease
Pacher, P., Beckman, J. S., & Liaudet, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00029.2006 · Cited by 6,390
“Although various mechanisms, including neuroinflammation, oxidative stress, autoimmunity, a defect in neuronal glutamate transport and glutamate toxicity, neurofilament accumulation, exogenous factors (viruses, toxins), mitochondrial dysfunction, and mutations in the SOD gene were implicated to play a role, the pathog…”
BackgroundAmyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
“In a small subset of familial Alzheimer's disease (FAD) cases, mutations have been identified in genes that encode the amyloid precursor protein (APP), presenilin-1 (PS1) or PS2 (Ref”
BackgroundHeras-Sandoval, D., Pérez-Rojas, J. M., Hernández-Damián, J., & Pedraza-Chaverri, J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.08.019 · Cited by 1,091
ER stress and the unfolded protein response in neurodegeneration
Hetz, C., & Saxena, S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.99 · Cited by 1,013
Human Health Risk Assessment for Aluminium, Aluminium Oxide, and Aluminium Hydroxide
Krewski, D., Yokel, R. A., Nieboer, E., Borchelt, D., Cohen, J., Harry, J., Kacew, S., Lindsay, J., Mahfouz, A. M., & Rondeau, V. (2007) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937400701597766 · Cited by 998
“Early onset AD is strongly linked to mutations in 3 genes, with autosomal-dominant inheritance patterns ( Bertram & Tanzi, 2004 ; 2005 ).”
Background
Metadata
- Authors
- Bertram, L.
- Affiliations
- Harvard University (US)
- Corresponding author
- Bertram, L.
- ORCID
- Bertram, L.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1449-1457
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1137006
- OpenAlex
- W2110054485
- Cited by
- 680
- References
- 106
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 40 · 2023: 48 · 2022: 48 · 2021: 40 · 2020: 44 · 2019: 37 · 2018: 46 · 2017: 41 · 2016: 36 · 2015: 20 · 2014: 25 · 2013: 25 · 2012: 34
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- Massachusetts General Hospital
- National Alliance for Research on Schizophrenia and Depression
- Deutsche Forschungsgemeinschaft
- National Institute on Aging
- National Institute of Mental Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- neurodegenerative diseases, genetic epidemiology, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington's disease, prion disease, common disease-common variant hypothesis, complex disease genetics, familial aggregation, genetic risk factors, single nucleotide polymorphisms, gene-environment interaction, genetic heterogeneity, pathogenesis, amyloid precursor protein, alpha-synuclein, tau protein
- MeSH terms
- Chromosome Mapping, Nerve Degeneration, Molecular Epidemiology, Neurodegenerative Diseases, Genetic Predisposition to Disease, Physical Chromosome Mapping
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.